Aurinia Pharmaceuticals Inc.AUPHNASDAQ
LOADING
|||
Net Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
46.66%
↑ 38% above average
Average (39q)
33.77%
Historical baseline
Range
High:1887.53%
Low:-523.97%
CAGR
+1.8%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 46.66% |
| Q2 2025 | -7.84% |
| Q1 2025 | 1533.59% |
| Q4 2024 | -90.04% |
| Q3 2024 | 1887.53% |
| Q2 2024 | 106.72% |
| Q1 2024 | 60.00% |
| Q4 2023 | -99.86% |
| Q3 2023 | -17.01% |
| Q2 2023 | 56.15% |
| Q1 2023 | -0.61% |
| Q4 2022 | -189.75% |
| Q3 2022 | 74.69% |
| Q2 2022 | 5.62% |
| Q1 2022 | -12.93% |
| Q4 2021 | 33.69% |
| Q3 2021 | -6.90% |
| Q2 2021 | 6.69% |
| Q1 2021 | -523.97% |
| Q4 2020 | 80.84% |
| Q3 2020 | -58.72% |
| Q2 2020 | -2.36% |
| Q1 2020 | 66.09% |
| Q4 2019 | -301.74% |
| Q3 2019 | -19.72% |
| Q2 2019 | -27.94% |
| Q1 2019 | 14.84% |
| Q4 2018 | 20.44% |
| Q3 2018 | -16.78% |
| Q2 2018 | -1.48% |
| Q1 2018 | -364.53% |
| Q4 2017 | 74.60% |
| Q3 2017 | -446.89% |
| Q2 2017 | 95.38% |
| Q1 2017 | -523.32% |
| Q4 2016 | -12.32% |
| Q3 2016 | -126.47% |
| Q2 2016 | 23.22% |
| Q1 2016 | -8.38% |
| Q4 2015 | 23.63% |